Thursday, October 23, 2025
2:00PM – 3:00PM ET
Please note this TeleECHO program is 2:00PM Eastern, 1:00PM Central, 12:00PM Mountain and 11:00AM Pacific.
PRESENTING FACULTY
 |
Benjamin P. Levy, MD Associate Professor of Oncology Johns Hopkins School of Medicine Baltimore, Maryland Clinical Director of Medical Oncology Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Washington, DC, USA |
PROGRAM OVERVIEW
This new educational series is intended for community oncologists who diagnose and care for patients with non-small cell lung cancer (NSCLC), primarily in the USA, but also globally. It aims to help these providers better understand the role of trophoblast cell-surface antigen 2 (TROP2) in the pathophysiology of NSCLC and the rationale behind targeting TROP2 in select patients with heavily treated advanced NSCLC. The series will also highlight the advances in developing TROP2-targeting antibody-drug conjugates (ADCs), discuss pivotal clinical trial data showing their efficacy and safety stratified by tumor histology and molecular genetics, and discuss their unique adverse event profiles. Clinicians will learn to develop personalized treatment plans by increasing their familiarity with emerging and recently approved TROP2-targeting ADCs in specific populations of patients with NSCLC and will further recognize the importance of incorporating a multidisciplinary approach to management of the unique adverse events associated with TROP2 ADCs.
TARGET AUDIENCE
This educational activity is intended for community oncologists who diagnose and care for patients with non-small cell lung cancer, primarily in the USA, but also globally.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the role of TROP2 signaling in the pathophysiology of NSCLC and the rationale for TROP2-targeted ADCs
- Analyze the latest clinical trial data for TROP2-targeted ADCs to inform treatment selection for patients with NSCLC
- Summarize the adverse event monitoring requirements for TROP2-targeted ADCs and best practices for managing emerging events in patients with NSCLC
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education (CE) for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
